Presentations
Stay Informed.

Presentations

Our Key Presentations

Filter

Presentations

Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment. (Abstract)

Event: 2024 Oligonucleotide Therapeutics Society Meeting (Montreal) View Abstract

October 11, 2024

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

Event: 2024 TIDES Asia Conference (Tokyo Japan) View Poster

March 21, 2024

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

Event: 2023 Annual OTS Conference (Barcelona Spain) View Poster

November 2, 2023

SCAD: a platform technology for CNS delivery of duplex RNA by intrathecal administration (Poster)

Event: 2023 Annual OTS Conference (Barcelona Spain) View Poster

November 2, 2023

Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. (Abstract)

Event: 2023 American Society of Clinical Oncology Meeting (Chicago) View Abstract

June 7, 2023

siRNA-ACO is a convenient phosphoramidite-based conjugate that enables RNAi in the CNS via local administration with superior efficacy in the treatment of ALS rodent models (Poster)

Event: 2023 TIDES USA (San Diego) View Poster

May 12, 2023

Presentations
Stay Informed.

Presentations

Our Key Presentations

Filter

Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment. (Abstract)

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

SCAD: a platform technology for CNS delivery of duplex RNA by intrathecal administration (Poster)

Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. (Abstract)

siRNA-ACO is a convenient phosphoramidite-based conjugate that enables RNAi in the CNS via local administration with superior efficacy in the treatment of ALS rodent models (Poster)

Join Us

CONTACT US

Follow Us

Presentations Stay Informed.

Presentations

Our Key Presentations

Filter

Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment. (Abstract)

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

SCAD: a platform technology for CNS delivery of duplex RNA by intrathecal administration (Poster)

Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. (Abstract)

siRNA-ACO is a convenient phosphoramidite-based conjugate that enables RNAi in the CNS via local administration with superior efficacy in the treatment of ALS rodent models (Poster)

Join Us

CONTACT US

Follow Us

Presentations
Stay Informed.